natgillin/translations-raw huggingface dataset:
Alternativ eller yderligere prævention anbefales ved coadministration af østrogenbaseret prævention med Symtuza. 
Alternative or additional contraceptive measures are recommended when oestrogen based contraceptives are coadministered with Symtuza.
De hyppigst indrapporterede bivirkninger er hæmatologiske forstyrrelser (anæmi, neutropeni) og metaboliske forstyrrelser (hyperlactatæmi, hyperlipasæmi). 
The main adverse reactions reported are haematological disorders (anaemia, neutropenia) and metabolic disorders (hyperlactataemia, hyperlipasaemia).
Symtuza kan co-administreres med protonpumpehæmmere uden dosisjustering. 
Symtuza can be co-administered with proton pump inhibitors without dose adjustments.
FDA-snapshot-resultater Hiv-1 RNA <50 kopier/ml Virologisk svigt 
FDA Snapshot Outcome HIV-1 RNA < 50 copies/mL Virologic Failure
Klinisk monitorering af terapeutisk virkning og bivirkninger anbefales, når disse lægemidler administreres samtidigt med Symtuza. 
Clinical monitoring of therapeutic and adverse effects is recommended when these medicines are co-administered with Symtuza.
(CYP3A-hæmning) Co-administration af ciclosporin forventes at øge plasmakoncentrationen af tenofoviralafenamid. 
(CYP3A inhibition) Co-administration of ciclosporin is expected to increase plasma concentrations of tenofovir alafenamide.
Hvis en dosis Symtuza glemmes i op til 12 timer efter det tidspunkt, hvor den sædvanligvis tages, skal patienterne informeres om snarest muligt at tage den ordinerede dosis Symtuza sammen med mad. 
If a dose of Symtuza is missed within 12 hours of the time it is usually taken, patients should be instructed to take the prescribed dose of Symtuza with food as soon as possible.
I det dobbeltblindede fase-3-studie TMC114FD2HTX3001 (AMBER) blev behandlingsnaive patienter randomiseret til at få enten Symtuza (N = 362) eller en kombination af en fastdosis-kombination af darunavir og cobicistat og en fastdosis-kombination af emtricitabin og tenofovirdisoproxilfumarat (F/TDF) (N = 363) en gang dagligt. 
In double-blind Phase 3 Trial TMC114FD2HTX3001 (AMBER), treatment-naïve patients were randomised to receive either Symtuza (N = 362) or a combination of fixed-dose combination of darunavir and cobicistat and fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate (F/TDF) (N = 363) once daily.
Virologiske resultater ved uge 48 og 96 i EMERALD-studiet Uge 48 
Week 48 and 96 Virologic Outcomes in EMERALD Trial Week 48
Behandling med Symtuza bør derfor ikke påbegyndes under graviditet, og kvinder, som bliver gravide under behandling med Symtuza, bør skiftes til et alternativt regime (se pkt. 
Therefore, therapy with Symtuza should not be initiated during pregnancy, and women who become pregnant during therapy with Symtuza should be switched to an alternative regimen (see sections 4.2 and 4.4).
Da Symtuza indeholder darunavir, cobicistat, emtricitabin og tenofoviralafenamid, kan der forventes de samme bivirkninger som dem, der er forbundet med de enkelte stoffer. 
As Symtuza contains darunavir, cobicistat, emtricitabine, and tenofovir alafenamide, the adverse reactions associated with each of the individual compounds may be expected.
Behandling med 800/150 mg darunavir/cobicistat en gang dagligt under graviditet fører til lav eksponering for darunavir (se tabel 8). 
Treatment with darunavir/cobicistat 800/150 mg once daily during pregnancy results in low darunavir exposure (see Table 8).
6 celler/l). 
6 cells/L),
Patienterne havde en medianalder på 46 år (interval 19-78), 82 % var mænd, 75,5 % hvide, 20,9 % sorte og 2,3 % asiater. 
Patients had a median age of 46 years (range 19-78), 82% were male, 75.5% White, 20.9% Black, and 2.3% Asian.
Der er ikke udført interaktionsstudier med Symtuza. 
No drug interaction trials have been performed using Symtuza.
De hyppigst rapporterede bivirkninger (> 5 %) hos supprimerede, behandlingserfarne patienter (EMERALD-studiet TMC114IFD3013, uge 96-analyse) var diarré (10,5 %), hovedpine (10,4 %), artralgi (7,7 %), abdominalsmerter (7,5 %), træthed (5,9 %) og udslæt (5,1 %). 
The most frequent (> 5%) adverse reactions reported in suppressed treatment-experienced patients (EMERALD Study TMC114IFD3013, Week 96 analysis) were diarrhoea (10.5%), headache (10.4%), arthralgia (7.7%), abdominal pain (7.5%), fatigue (5.9%), and rash (5.1%).
Forsigtighed tilrådes, og monitorering af den terapeutiske koncentration anbefales om muligt, når disse antiarytmika administreres samtidig med Symtuza. 
Caution is warranted and therapeutic concentration monitoring, if available, is recommended for these antiarrhythmics when co-administered with Symtuza.
Symtuza 800 mg/150 mg/200 mg/10 mg filmovertrukne tabletter 
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets
Metabolisme og ernæring almindelig diabetes mellitus, anoreksi, hyperkolesterolæmi, forhøjet LDL-kolesterol, hypertriglyceridæmi, hyperlipidæmi, dyslipidæmi ikke almindelig hyperglykæmi 
Metabolism and nutrition disorders common diabetes mellitus, anorexia, hypercholesterolaemia, low density lipoprotein increased, hypertriglyceridaemia, hyperlipidaemia, dyslipidaemia uncommon hyperglycaemia
I fase 3-studiet hos supprimerede, behandlingserfarne patienter (EMERALD-studiet TMC114IFD3013) oplevede 5,1 % (39/763) af de patienter, der fik Symtuza, udslæt (af hvilke de fleste var af grad 1), ingen afbrød behandlingen på grund af udslæt. 
In the Phase 3 trial in suppressed treatment-experienced patients (EMERALD Study TMC114IFD3013), 5.1% (39/763) of patients receiving Symtuza experienced rash (most of which were grade 1), none discontinued treatment due to rash.
Gennemsnitligt baseline plasma hiv-1 RNA og medianen for CD4+-celletal ved baseline var henholdsvis 4,48 log10 kopier/ml (SD = 0,61) og 453 x 10 
The mean baseline plasma HIV-1 RNA and the median baseline CD4+ cell count were 4.48 log10 copies/mL (SD = 0.61) and 453 x 10
I forbindelse med svangerskabsforebyggelse anbefales det, at du anvender prævention, der ikke indeholder hormoner. 
When used for birth control, non-hormonal contraception methods are recommended.
Co-administration af Symtuza og sildenafil til behandling af pulmonal arteriel hypertension er derfor kontraindiceret (se pkt. 
Therefore, co-administration of Symtuza and sildenafil when used for the treatment of pulmonary arterial hypertension is contraindicated (see section 4.3).
• muskelsmerter, muskelkramper eller muskelsvaghed 
• muscle pain, muscle cramps or weakness
HMG-CO-A-REDUKTASEHÆMMERE Atorvastatin 
HMG CO-A REDUCTASE INHIBITORS Atorvastatin
Ny resistens hos hiv 1-inficerede, behandlingsnaive og virologisk supprimerede patienter 
Emerging resistance in HIV-1 infected, treatment-naïve and virologically suppressed patients
(lægemiddel)overfølsomhed ikke almindelig immunrekonstitutionsinflammatorisk syndrom 
(drug) hypersensitivity uncommon immune reconstitution inflammatory syndrome
Darunavir er en CYP3A-hæmmer, en svag CYP2D6-hæmmer og en P-gp-hæmmer. 
Darunavir is an inhibitor of CYP3A, a weak inhibitor of CYP2D6 and an inhibitor of P-gp.
Gul til gullig-brun kapselformet, filmovertrukket tablet, hvor der står „8121“ på den ene side og „JG“ på den anden side. 
What Symtuza looks like and contents of the pack Yellow to yellowish-brown capsule shaped film-coated tablet, mentioning “8121” on one side and “JG” on the other side.
Afbrydelse af behandlingen med Symtuza hos patienter med samtidig hiv- og HBV-infektion kan føre til alvorlig, akut forværring af hepatitis. 
Discontinuation of Symtuza therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis.
Ved baseline var gennemsnitligt hiv-1 RNA i plasma 4,7 log10 kopier/ml, middel CD4+-celletal var 456 celler/mm 
At baseline, median plasma HIV-1 RNA was 4.7 log10 copies/mL, median CD4+ cell count was 456 cells/mm
(CYP3A-induktion) Symtuza forventes at øge plasmakoncentrationen af bosentan. 
(CYP3A induction) Symtuza is expected to increase bosentan plasma concentrations.
Baseret på teoretiske overvejelser kan co-administration af DRV/COBI med disse antikoagulantia øge koncentrationen af antikoagulansen, hvilket kan medføre en øget blødningsrisiko. 
Based on theoretical considerations co-administration of DRV/COBI with these anticoagulants may increase concentrations of the anticoagulant, which may lead to an increased bleeding risk.
De hyppigst rapporterede bivirkninger (> 5 %) hos behandlingsnaive patienter i fase 2-studiet (GS299-0102) og fase 3-studiet (AMBER, TMC114FD2HTX3001, uge 96-analyse) var diarré (22,6 %), hovedpine (13,1 %), udslæt (12,7 %), kvalme (9,7 %), træthed (8,0 %) og abdominalsmerter (5,8 %). 
The most frequent (> 5%) adverse reactions reported in treatment-naïve patients in the Phase 2 (GSUS-299-0102) and Phase 3 Study (AMBER, TMC114FD2HTX3001, Week 96 analysis) were diarrhoea (22.6%), headache (13.1%), rash (12.7%), nausea (9.7%), fatigue (8.0%), and abdominal pain (5.8%).
Dosisreduktion af fesoterodin eller solifenacin kan være nødvendig. 
Monitor for fesoterodine or solifenacin adverse reactions, dose reduction of fesoterodine or solifenacin may be necessary.
Den anbefalede dosis til voksne og unge i alderen 12 år og derover, der vejer mindst 40 kg, er én tablet, der tages én gang dagligt sammen med mad. 
The recommended dose for adults and adolescents 12 years of age and older, who weigh at least 40 kg is one tablet each day with food.
Tenofoviralafenamid er en nukleotid revers transkriptasehæmmer (NtRTI) og et phosphonoamidatprodrug for tenofovir (2'-deoxyadenosinmonophosphat-analog). 
Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI) and phosphonoamidate prodrug of tenofovir (2'-deoxyadenosine monophosphate analogue).
• opkastning, mavesmerter eller -udspiling, fordøjelsesbesvær, luft i tarmene 
• vomiting, pain or swelling of the belly, indigestion, flatulence (wind)
Det skal du vide, før du begynder at tage Symtuza 
What you need to know before you take Symtuza
Udslæt er en almindelig bivirkning hos patienter, der er i behandling med darunavir. 
Rash is a common adverse drug reaction in patients treated with darunavir.
Det er ukendt, om darunavir, cobicistat eller tenofoviralafenamid udskilles i human mælk. 
It is not known whether darunavir, cobicistat, or tenofovir alafenamide are excreted in human milk.
Symtuza, skal monitoreres tæt både med klinisk og laboratoriemæssig opfølgning i mindst flere måneder efter afbrydelsen af behandlingen. 
Patients co-infected with HIV and HBV who discontinue Symtuza should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment.
Effekten af svært nedsat leverfunktion (Child-Pugh klasse C) på cobicistats farmakokinetik er ikke blevet undersøgt. 
The effect of severe hepatic impairment (Child-Pugh Class C) on the pharmacokinetics of cobicistat has not been studied.
Symtuzas farmakokinetik er ikke blevet undersøgt hos pædiatriske patienter. 
The pharmacokinetics of Symtuza have not been investigated in paediatric patients.
Janssen-Cilag SpA Via C. Janssen, Borgo San Michele 
Via C. Janssen, Borgo San Michele
Hiv-1 RNA ≥50 kopier/ml Virologisk svigt, der medførte afbrydelse Forsøgsmedicin seponeret af andre årsager og seneste tilgængelige hiv-1 RNA ≥50 kopier/ml 
HIV-1 RNA ≥ 50 copies/mL Virologic Failure Leading to Discontinuation Discontinued study drug due to other reasons and last available HIV-1 RNA ≥ 50 copies/mL
In vivo hydrolyseres tenofoviralafenamid i cellerne, hvorved der dannes tenofovir (primær metabolit), som fosforyleres til den aktive metabolit tenofovirdiphosphat. 
In vivo, tenofovir alafenamide is hydrolysed within cells to form tenofovir (major metabolite), which is phosphorylated to the active metabolite tenofovir diphosphate.
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af fluvastatin, pitavastatin, pravastatin, lovastatin og simvastatin. 
Based on theoretical considerations DRV/COBI is expected to increase the plasma concentrations of fluvastatin, pitavastatin, pravastatin, lovastatin and simvastatin.
Co-administration af Symtuza med oxcarbazepin frarådes. 
Co-administration of Symtuza with oxcarbazepine is not recommended.
Der foreligger ingen data om virkningen af darunavir, cobicistat, emtricitabin eller tenofoviralafenamid på fertiliteten hos mennesker. 
No human data on the effect of darunavir, cobicistat, emtricitabine, or tenofovir alafenamide on fertility are available.
• allergiske reaktioner såsom nældefeber (urticaria), kløe 
• allergic reactions such as nettle rash (urticaria), itching, decreased appetite (anorexia)
Anvendes inden 6 uger efter første åbning af beholderen. 
Do not use this medicine after 6 weeks of first opening the bottle.
Effekten af svært nedsat leverfunktion (Child-Pugh klasse C) på tenofoviralafenamids farmakokinetik er ikke blevet undersøgt. 
The effect of severe hepatic impairment (Child-Pugh Class C) on the pharmacokinetics of tenofovir alafenamide has not been studied.
Hos nogle patienter med fremskreden hiv-infektion (aids), som tidligere har haft opportunistiske infektioner (usædvanlige infektioner på grund af et svækket immunforsvar), kan tegn og symptomer på betændelse fra tidligere infektioner vise sig kort efter påbegyndelse af hiv-behandling, også med Symtuza. 
In some patients with advanced HIV infection (AIDS) and a history of opportunistic infection (unusual infections due to a weakened immune system), signs and symptoms of inflammation from previous infections may occur soon after HIV treatment is started, including Symtuza.
• forstørrelse af bryster 
• enlargement of breasts
Forsøgsmedicin seponeret af andre årsager og seneste tilgængelige hiv-1 RNA < 50 kopier/ml Manglende data i vinduet men med i studiet Virologisk respons (hiv-1-RNA <50 kopier/ml; snapshot-analyse) efter undergruppe, n/N (%) Alder <50 år ≥50 år 
Discontinued study drug due to other reasons and last available HIV-1 RNA < 50 copies/mL Missing data during window but on trial Virologic response (HIV-1-RNA < 50 copies/mL; Snapshot Analysis) by subgroup, n/N (%)
Mave-tarm-kanalen meget almindelig diarré almindelig opkastning, kvalme, abdominalsmerter, abdominal distention, dyspepsi, flatulens ikke almindelig akut pankreatitis, forhøjede pankreasenzymer 
Gastrointestinal disorders very common diarrhoea common vomiting, nausea, abdominal pain, abdominal distension, dyspepsia, flatulence uncommon pancreatitis acute, pancreatic enzymes increased
Cobicistat er en mekanismebaseret CYP3A-hæmmer og en svag CYP2D6-hæmmer. 
Cobicistat is a mechanism based inhibitor of CYP3A, and a weak CYP2D6 inhibitor.
Alle viste en aktivitet over for vildtype hiv, der var mindst 10 gange mindre end darunavirs aktivitet. 
At least 3 oxidative metabolites of darunavir have been identified in humans; all showed activity that was at least 10-fold less than the activity of darunavir against wild type HIV.
KORTIKOSTEROIDER Budesonid 
CORTICOSTEROIDS Budesonide
Lægemidler, der inducerer CYP3A-aktivitet, må forventes at øge clearance af darunavir og cobicistat, hvilket kan medføre en lavere plasmakoncentration af darunavir og cobicistat (f.eks. efavirenz, carbamazepin, phenytoin, phenobarbital, rifampicin, rifapentin, rifabutin, perikon) (se pkt. 
Medicinal products that induce CYP3A activity would be expected to increase the clearance of darunavir and cobicistat, resulting in lowered plasma concentrations of darunavir and cobicistat (e.g. efavirenz, carbamazepine, phenytoin, phenobarbital, rifampicin, rifapentine, rifabutin, St. John's wort) (see section 4.3 and interaction table below).
Co-administration af oral midazolam eller triazolam og Symtuza er kontraindiceret (se pkt. 
Co-administration of oral midazolam or triazolam and Symtuza is contraindicated (see section 4.3).
Symtuza skal seponeres hos patienter med eGFRCG, der falder til under 30 ml/min under behandling (se pkt. 
Symtuza should be discontinued in patients with eGFRCG that declines below 30 mL/min during treatment (see sections 5.1 and 5.2).
Med Cyst C som filtrationsmarkør blev middelændringen i estimeret glomerulær filtrationshastighed beregnet ved hjælp af formlen CKD-EPI (eGFRCKD-EPI CystC) til henholdsvis 4,0 ml/min/1,73 m² og 1,6 ml/min/1,73 m² (p<0,001). 
Using Cyst C as filtration marker, the median changes in estimated glomerular filtration rate calculated using the CKD-EPI (eGFRCKD-EPI CystC) formula were respectively 4.0 mL/min/1.73 m² and 1.6 mL/min/1.73 m² (p<0.001).
Inkluderede forsøgspersoner, som havde ≥50 kopier/ml i uge 48/96-vinduet; forsøgspersoner, som afbrød behandlingen før tid på grund af manglende virkning eller tab af virkning i henhold til investigators vurdering; forsøgspersoner, som afbrød behandlingen af andre årsager end bivirkning (AE), død eller manglende virkning eller tab af virkning, og som på tidspunktet for afbrydelsen havde en viral værdi ≥ 50 kopier/ml. 
Included subjects who had ≥ 50 copies/mL in the Week 48/96 window; subjects who discontinued early due to lack or loss of efficacy per investigator's assessment; subjects who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral value ≥ 50 copies/mL.
Baseret på teoretiske overvejelser kan co-administration af DRV/COBI med dabigatran eller ticagrelor øge koncentrationen af antikoagulansen. 
Based on theoretical considerations co-administration of DRV/COBI with dabigatran or ticagrelor may increase concentrations of the anticoagulant.
Darunavirs mediane terminale plasmahalveringstid efter administration af Symtuza er 5,5 timer. 
The median terminal plasma half-life of darunavir following administration of Symtuza is 5.5 hours.
Kombination af colchicin og Symtuza er kontraindiceret hos patienter med nedsat nyre- eller leverfunktion (se pkt. 
The combination of colchicine and Symtuza is contraindicated in patients with renal or hepatic impairment (see section 4.3).
Dosisreduktion af disse neuroleptika bør overvejes ved co-administration med Symtuza. 
For these neuroleptics, consider reducing the dose of the neuroleptic upon co-administration with Symtuza.
Fjernelse af det børnesikrede låg 
Removing the child resistant cap
Co-administration af amiodaron, dronedaron, ivabradin, kinin eller ranolazin og Symtuza er kontraindiceret (se pkt. 
Co-administration of amiodarone, dronedarone, ivabradine, quinidine, or ranolazine and Symtuza is contraindicated (see section 4.3).
(Hæmning af P-glykoprotein) 
(P-glycoprotein inhibition)
Kombinationen af lurasidon, pimozid, quetiapin eller sertindol og Symtuza er kontraindiceret (se pkt. 
The combination of lurasidone, pimozide, quetiapine or sertindole and Symtuza is contraindicated (see section 4.3).
Behandling med darunavir/cobicistat (to af indholdsstofferne i Symtuza) under graviditet fører til lav eksponering for darunavir (se pkt. 
Treatment with darunavir/cobicistat (two of the components of Symtuza) during pregnancy results in low darunavir exposure (see sections 4.4 and 5.2).
Symtuza er ikke blevet undersøgt hos patienter med svært nedsat leverfunktion (Child-Pugh klasse C), og Symtuza må derfor ikke anvendes til patienter med svært nedsat leverfunktion (se pkt. 
Symtuza has not been studied in patients with severe hepatic impairment (Child-Pugh Class C), therefore, Symtuza must not be used in patients with severe hepatic impairment (see sections 4.3, 4.4 and 5.2).
Klinisk monitorering anbefales ved co-administration af Symtuza med betablokkere, og en lavere dosis af betablokkeren bør overvejes. 
Clinical monitoring is recommended when co-administering Symtuza with beta-blockers and a lower dose of the beta-blocker should be considered.
Emtricitabin er en nukleosid revers-transkriptasehæmmer (NRTI) og en nukleosidanalog af 2'-deoxycytidin. 
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and nucleoside analogue of 2'-deoxycytidine.
Patienter med samtidig hiv- og hepatitis B- eller C-virusinfektion 
Patients co-infected with HIV and hepatitis B or C virus
Der er ikke blevet identificeret klinisk relevante farmakokinetiske forskelle for cobicistat, emtricitabin eller tenofoviralafenamid på grund af alder i aldersgruppen ≤ 65 år. 
No clinically relevant pharmacokinetic differences due to age have been identified for cobicistat, emtricitabine or tenofovir alafenamide in the age range ≤ 65 years.
Croscarmellosenatrium Magnesiumstearat Cellulose, mikrokrystallinsk Silica, kolloid, vandfri 
Croscarmellose sodium Magnesium stearate Cellulose, microcrystalline Silica, colloidal anhydrouse
• Hvis du kommer i tanke om den glemte dosis inden for 12 timer efter det tidspunkt, hvor du normalt tager Symtuza, skal du straks tage en tablet sammen med mad. 
• If you notice within 12 hours of the time you usually take Symtuza, you must take the tablet immediately, with food.
Med Cyst C som filtrationsmarkør blev middelændringen i estimeret glomerulær filtrationshastighed beregnet ved hjælp af formlen CKD-EPI (eGFRCKD-EPI CystC) (N=22) til +4,4 ml/min/1,73 m2 med D/C/F/TAF. 
Using Cyst C as filtration marker, the median change in estimated glomerular filtration rate calculated using the CKD-EPI (eGFRCKD-EPI Cyst C) formula (N=22) was +4.4 mL/min/1.73 m² with D/C/F/TAF.
Tenofoviralafenamids antivirale aktivitet mod laboratorie- og kliniske isolater af hiv-1 undertype B blev vurderet i lymfoblastoide cellelinjer, PBMC'er, primære monocyt-/makrofag-celler og CD4+-T-lymfocytter. 
The antiviral activity of tenofovir alafenamide against laboratory and clinical isolates of HIV-1 subtype B was assessed in lymphoblastoid cell lines, PBMCs, primary monocyte/macrophage cells and CD4+-T lymphocytes.
Det frarådes at co-administrere boostet Symtuza og glecaprevir/pibrentasvir. 
It is not recommended to co-administer Symtuza with glecaprevir/pibrentasvir.
CD4+-celletal, gennemsnitlig ændring fra baseline 
CD4+ cell count mean change from baseline
Der er kun begrænset erfaring med akut overdosering af Symtuza hos mennesker. 
Human experience of acute overdose with Symtuza is limited.
Klinisk monitorering anbefales ved co-administration af Symtuza med kortikosteroider. 
Clinical monitoring is recommended when co-administering Symtuza with corticosteroids.
Lever og galdeveje almindelig forhøjede leverenzymer ikke almindelig akut hepatitis a, cytolytisk hepatitis 
Hepatobiliary disorders common hepatic enzyme increased uncommon acute hepatitis a, cytolytic hepatitis
Der blev ikke observeret klinisk relevante forskelle i cobicistats farmakokinetik mellem personer med moderat nedsat funktion og raske personer. 
No clinically relevant differences in cobicistat pharmacokinetics were observed between subjects with moderate impairment and healthy subjects.
Der udvistes ingen speciel risiko for mennesker i konventionelle studier af karcinogent potentiale og reproduktions- og udviklingstoksicitet. 
No special hazard for humans was revealed in conventional studies of carcinogenic potential and toxicity to reproduction and development.
Der blev ikke observeret nogen klinisk relevante forskelle i cobicistats farmakokinetik hos personer med svært nedsat nyrefunktion sammenlignet med raske personer, hvilket er i overensstemmelse med cobicistats lave renale clearance. 
No meaningful differences in cobicistat pharmacokinetics were observed between subjects with severe renal impairment and healthy subjects, consistent with low renal clearance of cobicistat.
Symtuza indeholder: 
What Symtuza contains
Aluminium/magnesiumhydroxid Calciumcarbonat 
ANTACIDS Aluminium/magnesium hydroxide
Hvis du har taget for mange Symtuza 
If you take more Symtuza than you should